Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Aniracetam is a nootropic compound belonging to the racetam family, primarily researched for cognitive enhancement. Its potential use in depression is based on preclinical and limited clinical studies. Animal studies have demonstrated that Aniracetam exhibits antidepressant-like effects, possibly through modulation of glutamatergic and cholinergic neurotransmission and enhancement of AMPA receptor activity. These effects may also influence serotonin and dopamine systems, which are implicated in mood regulation.

Human evidence is limited. A few small and low-quality clinical studies (mostly from Russia and Japan) suggest that Aniracetam may improve symptoms of depression and anxiety, particularly in elderly patients with cognitive decline. However, these studies are often open-label, lack placebo controls, and involve small sample sizes, limiting the strength of the conclusions.

Major regulatory agencies such as the FDA or EMA have not approved Aniracetam for the treatment of depression, and large, well-controlled clinical trials are lacking. Although there is some scientific rationale and early evidence for its use in depressive symptoms, the supporting data is weak and insufficient for clinical recommendations. Therefore, while there is a scientific basis for investigating Aniracetam in depression, the evidence is preliminary and not robust.

More about Aniracetam
More about Depression

Other ingredients used for Depression

Other health conditions supported by Aniracetam

Products containing Aniracetam